Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Isofol Medical AB (publ)
  6. Summary
    ISOFOL   SE0009581051

ISOFOL MEDICAL AB (PUBL)

(ISOFOL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
8.54(c) 8.75(c) 8.45(c) 8.93(c) 8.62(c) Last
115 686 498 464 237 288 371 291 183 634 Volume
-2.84% +2.46% -3.43% +5.68% -3.47% Change
More quotes
Estimated financial data (e)
Sales 2021 19,8 M 2,15 M 2,15 M
Net income 2021 -190 M -20,7 M -20,7 M
Net cash position 2021 319 M 34,7 M 34,7 M
P/E ratio 2021 -6,82x
Yield 2021 -
Sales 2022 100 M 10,9 M 10,9 M
Net income 2022 -214 M -23,3 M -23,3 M
Net cash position 2022 348 M 37,9 M 37,9 M
P/E ratio 2022 -6,48x
Yield 2022 -
Capitalization 1 392 M 152 M 151 M
EV / Sales 2021 54,2x
EV / Sales 2022 10,4x
Nbr of Employees 15
Free-Float -
More Financials
Company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not... 
Sector
Pharmaceuticals
Calendar
02/25Earnings Release
More about the company
Ratings of Isofol Medical AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ISOFOL MEDICAL AB (PUBL)
2021Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer
AQ
2021Isofol Medical AB Appoints Jenny Sundqvist as Chief Commercial Officer
CI
2021ISOFOL MEDICAL : – Company Presentation >>
PU
2021DNB MARKETS - ISOFOL MEDICAL : áPotential approval still possible
AQ
2021Isofol Medical Mulls Changing Secondary Goal in Late-Stage Colorectal Cancer Study
MT
2021Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET
AQ
2021Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current ..
AQ
2021Isofol Medical AB Will Not Reach 300 PFS Events in the Agent Study with Current Censori..
CI
2021Isofol Medical's Metastatic Colorectal Cancer Treatment Granted Fast Track Designation ..
MT
2021Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advan..
AQ
2021Isofol Medical AB Receives FDA Fast Track Designation for Arfolitixorin in Advanced Col..
CI
2021Isofol appoints nomination committee ahead of the Annual General Meeting 2022
AQ
2021Isofol Medical AB Appoints Nomination Committee
CI
2021Isofol Medical - AGENT on a Mission to Secure Critical Data
AQ
2021DNB MARKETS - ISOFOL MEDICAL : áIntensifying precommercial activities
AQ
More news
News in other languages on ISOFOL MEDICAL AB (PUBL)

- No features available -

More news
Chart ISOFOL MEDICAL AB (PUBL)
Duration : Period :
Isofol Medical AB (publ) Technical Analysis Chart | ISOFOL | SE0009581051 | MarketScreener
Technical analysis trends ISOFOL MEDICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 8,62 SEK
Average target price 23,00 SEK
Spread / Average Target 167%
EPS Revisions
Managers and Directors
Jarl Ulf Birger Jungnelius Chief Executive Officer
Gustaf AlbÚrt Chief Financial Officer
Pńr-Ola Mannefred Chairman
Karin Ganl÷v Senior Medical Director
Roger Tell Chief Medical Officer
Sector and Competitors